Merrion Pharmaceuticals: The oral immediate release formulation of alogliptin is expected to be selected for the twelfth batch of national centralized drug procurement.

Mei Nuo Hua announced that its wholly-owned subsidiary, Mei Nuo Hua Tian Kang, will participate in the twelfth batch of national centralized pharmaceutical procurement, with the oral immediate-release formulation of alogliptin expected to be selected. This medication is indicated for the treatment of type 2 diabetes, with a specification of 25mg*30 tablets/bottle. As of the end of June 2026, this product has not generated sales in the domestic market. The proposed selection results have been announced, but subsequent matters and impacts on the company's performance remain uncertain.